alexa Horizons in Novel Oral Anticoagulation Therapy in Concomitant Acute Coronary Syndromes and Atrial Fibrillation

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Horizons in Novel Oral Anticoagulation Therapy in Concomitant Acute Coronary Syndromes and Atrial Fibrillation

The ischemic risk in patients with acute coronary syndromes (ACS) persists after hospital discharge, even with proper antithrombotic therapy. The rate of cardiovascular death, non-fatal myocardial infarction (MI) or stroke during the first year after hospitalization is around 10%, despite antithrombotic and revascularization therapie.

Citation: Shihadeh LA, Fernández-Rodríguez D, Lorenzo-González J, Hernández-Afonso J (2015) Horizons in Novel Oral Anticoagulation Therapy in Concomitant Acute Coronary Syndromes and Atrial Fibrillation. Cardiol Pharmacol 4:155.

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger